Ο X. X. εξομολογείται...

Boy Πάντα πίστευα πως είμαι ξεχωριστός, ιδιόμορφος, πολύπλοκος σαν άνθρωπος και σαν χαρακτήρας. Μπαίνω συχνά στο site και διαβάζω τις ιστορίες των παιδιών.

Τις τελευταίες τρεις εβδομάδες, απο τότε δηλαδή που έμαθα πως είμαι οροθετικός, διαβάζω τις εξομολογήσεις και νιώθω σαν να τις έχω γράψει εγώ.
Έχω ακριβώς τα ίδια συναισθήματα, τις ιδίες ανησυχίες, τις ίδιες φοβίες. Ίσως ο καθένας μας να τις εξωτερικεύει διαφορετικά, αλλά μέσα μας να νιώθουμε τα ίδια πράγματα. Και είναι ανθρώπινα όλα αυτά.

Η μόνη αλλαγή που έχω παρατηρήσει έντονα είναι πως τα μάτια μου υγραίνουν πιο εύκολα από ότι παλιότερα (...ήμουν σκληρό παιδί). Ένας φίλος μου είπε: «Αυτό είναι καλό... καθαρίζουν και τα μάτια!»

Λένε πως οι άνθρωποι δεν αλλάζουν... και ίσως πραγματικά να μην αλλάζουν. Αλλάζουν όμως τα δεδομένα και τα δεδομένα έρχονται με την σειρά τους να αλλάξουν τον τρόπο που εκτιμάμε την ζωή μας. Δεν αδιαφορώ πλέον όταν ο φιλος μου, μου λέει: «σε αγαπώ».
Δεν θεωρώ δεδομένη μια ακόμα ηλιόλουστη μέρα. Παλιότερα, πολλές φορές δυσκολευόμουν να κοιμηθώ το βράδυ γιατί σκεφτόμουν την αυριανή δουλεία, με έπιανε το οικονομικό μου άγχος κτλ. Τώρα κοιμάμαι ήσυχα, σαν πουλάκι. Δεν σκέφτομαι απολύτως τίποτα. Δεν πιστεύω ότι έχω γίνει κυνικός και δεν θα ήθελα να γίνω. Ούτε θέλω να ζώ την κάθε μέρα σαν να ήταν η τελευταία, γιατί θέλω να συνεχίσω να κάνω σχέδια για τη ζωή μου.

Προσπαθώ αυτές τις μέρες να διαβάσω, να μάθω και να ενημερωθώ για το HIV, ώς παθών πλέον. Μιλάω στο internet με οροθετικούς και τους ρωτάω πως είναι να ζείς με τον ιό, πως είναι να δουλεύεις, να κάνεις sex. Όλοι μου λένε για να με καθυσηχάσουν: «Θα δείς με τον καιρό... μην ανησυχείς... δεν ήρθε το τέλος του κόσμου».

Δεν ξέρω τι μου επιφυλάσσει το μέλλον ως οροθετικός. Και δεν ξέρω αν θα περάσει μια μέρα, κατά το υπόλοιπο της ζωής μου, που να μην σκεφτώ τι έχω. Ξέρω όμως πως ότι και να γίνει, θα έχω την δυνατότητα της επιλογής. Αυτή δεν πρόκειται να μου την στερήσει κανένας ιός. Και έχω ήδη επιλέξει να συνεχίσω να ζω.

Χ.Χ.




... 'Aλλες ιστορίες ...



Differences between groups of pre-exposure prophylaxis (PrEP) using couples in HIV-negative/unknown relationships

Thu, 11 Apr 2019 00:00:00 GMT-05:00 - John, Steven A.; Robles, Gabriel; Starks, Tyrel J.; Rendina, H. Jonathon
Εισαγωγή: Epidemiology research is limited on the characteristics of HIV pre-exposure prophylaxis (PrEP) using couples. Setting: United States nationwide sample recruited online in 2017.
Μέθοδοι: HIV-negative/unknown gay, bisexual, and other men who have sex with men (GBMSM) with HIV-negative/unknown partners (n=3140) were asked about individual and main partner PrEP uptake. Men were coded into five groups: 1) neither participant nor partner on PrEP, 2) partner only on PrEP, 3) participant only on PrEP, 4) both on PrEP, and 5) unknown partner PrEP use. We examined associations of demographics, relationship factors, condomless anal sex (CAS) with main and causal partners, bacterial sexually transmitted infection (BSTI) diagnoses, and sexual positioning with reported dyadic PrEP use using fully-adjusted multinomial logistic regressions.
Αποτελέσματα: PrEP use was 3.2% for the partner only, 5.7% for the participant only, and 4.9% for both participant and partner; 5.6% reported not knowing their partner’s PrEP use status. Men who reported any CAS with their main partner or any CAS with male casual partners were both more likely to be classified in the dyadic PrEP use group compared to the neither on PrEP group. Compared to monogamous, men in open arrangements were more likely to be classified in each of the three PrEP groups compared to the neither on PrEP group. Six-month BSTI prevalence was 2.8%, 8.1%, 8.3%, 15.6%, and 4.0% for the five groups, respectively.
Συμπεράσματα: PrEP use occurred during times of higher risk behavior engagement, but further efforts are needed to expand PrEP use to more partnered GBMSM. Author to whom correspondence should be addressed; Address: 695 Park Avenue, Room N611, New York, NY 10065; Phone: 212-206-7919; Fax: 212-206-7994; Email: hrendina@hunter.cuny.edu Conflicts of Interest and Source of Funding: Funding: Steven A. John was supported by the Center for AIDS Intervention Research (CAIR) and the National Institute of Mental Health (P30-MH052776, PI: Jeffrey A. Kelly). Gabriel Robles received support from the National Institute on Drug Abuse (R01-DA045613-01S1, PI: Tyrel J. Starks, Awardee: Gabriel Robles). H. Jonathon Rendina was supported in part by a career development award from the National Institute on Drug Abuse (K01-DA039060; PI: H. Jonathon Rendina). Data collection for this paper was supported in part by the Fordham HIV and Drug Abuse Prevention Research Ethics Training Institute (RETI), a training grant sponsored by the National Institute on Drug Abuse (R25-DA031608, PI: Celia B. Fisher). The authors also acknowledge the generous funding provided by the offices of the President, the Provost, and the Dean of Arts & Sciences of Hunter College, CUNY; additional support was also provided by Hunter College’s Center for HIV/AIDS Educational Studies & Training (CHEST). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Fordham RETI, Medical College of Wisconsin, or Hunter College, CUNY. Conflict of Interest: The authors declare that they have no conflict of interest. Previous meeting where part of these data were presented: International Association of Providers of AIDS Care (IAPAC) Conference, Miami, FL. June 8-10, 2018. - Β© 2019

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Thu, 11 Apr 2019 00:00:00 GMT-05:00 - Johnson, Margaret; Kumar, Princy; Molina, Jean-Michel; Rizzardini, Giuliano; Cahn, Pedro; Bickel, Markus; Mallolas, Josep; Zhou, Yan; Morais, Cristiana; Kumar, Sushma; Sklar, Peter; Hanna, George J; Hwang, Carey; Greaves, Wayne; for the DRIVE-SHIFT Study Group
Εισαγωγή: Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor (NNRTI) with demonstrated efficacy in treatment-naΓ―ve adults with HIV.
Μέθοδοι: In this open-label, active-controlled, non-inferiority trial, adults with HIV virologically suppressed for ≥6 months on 2 NRTIs plus a boosted protease inhibitor (PI), boosted elvitegravir, or an NNRTI were randomized (2:1) to switch to once-daily, single-tablet doravirine 100mg with lamivudine 300mg and tenofovir disoproxil fumarate 300mg (DOR/3TC/TDF) or to continue their current therapy (Baseline Regimen) for 24 weeks. The primary endpoint was the proportion of participants with HIV RNA <50 copies/mL (FDA Snapshot approach), with the primary comparison between DOR/3TC/TDF at week 48 and Baseline Regimen at week 24, and a secondary comparison between the groups at week 24 (non-inferiority margin, -8%).
Αποτελέσματα: 670 participants (447 DOR/3TC/TDF, 223 Baseline Regimen) were treated and included in the analyses. At week 24, 93.7% on DOR/3TC/TDF vs 94.6% on Baseline Regimen had HIV RNA <50 copies/mL (difference -0.9 [-4.7, 3.0]). At week 48, 90.8% on DOR/3TC/TDF had HIV RNA <50 copies/mL, demonstrating non-inferiority vs Baseline Regimen at week 24 (difference -3.8 [-7.9, 0.3]). In participants on ritonavir-boosted PI at entry, mean reductions in fasting LDL-C and non-HDL-C at week 24 were significantly greater for DOR/3TC/TDF vs Baseline Regimen (p<0.0001). Adverse events occurred in 68.9% on DOR/3TC/TDF and 52.5% on Baseline Regimen by week 24, leading to treatment discontinuation in 2.5% and 0.4%, respectively.
Συμπεράσματα: Switching to once-daily DOR/3TC/TDF is a generally well-tolerated option for maintaining viral suppression in patients considering a change in therapy. Registration: ClinicalTrials.gov NCT02397096 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Corresponding Author: Wayne Greaves, MD, Merck Sharp & Dohme Corp., 126 E. Lincoln Avenue, RY34-A484, Rahway, NJ 07065-0900, (732) 594-3736, 305-7403, wayne.greaves@merck.com Conflicts of Interest and Source of Funding: Funding for this research was provided by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. MJ has received grants and consulting fees from Gilead and Viiv. PK is on Advisory Boards for ViiV, Janssen, Merck, and Theratechnologies; has received grants from Merck, ViiV, Gilead, and Theratechnologies; and owns stock in Johnson & Johnson, Gilead, Merck, Pfizer, and GSK. J-MM has received grants from Gilead and consulting fees (Advisory Board) from Gilead and MSD. GR has received Advisory board and speaker fees from JanssenCilag, Abbvie, Gilead Science, ViiV, MSD, and Angelini. PC is an Advisory Board member for MSD and ViiV and has received research grants from AbbVie, MSD, and ViiV. MB has no conflicts to declare. JM has received honoraria, speakers’ fees, consultant fees or funds for research from MSD, Roche, Boehringer-Ingelheim, ViiV, Gilead, Janssen, BMS, and Abbvie. YZ, CM, SK, PS, GJH, CH, and WG are current or former employees of MSD. Parts of the data were presented at: IDWeek 2018, San Francisco CA, 04-Oct-2018. - Β© 2019

About us

Στο hivaids.gr, φιλοξενούμε αφιλοκερδώς το "Πρόγραμμα Συνεργασίας" Μονάδων Λοιμώξεων για την ανάπτυξη διαδικτυακής τράπεζας κλινικών παραμέτρων. Το Πρόγραμμα δημιουργήθηκε από έναν γιατρό ειδικό στην HIV λοίμωξη με τη συμμετοχή των Μονάδων: Περισσότερα

% Αναπηρία και HIV

Νέος κανονισμός

Ενιαίος Πίνακας Προσδιορισμού Ποσοστού Αναπηρίας

Ημερολόγιο

@ Διαύγεια

ΔιαύγειαΔι@ύγεια

διαφάνεια στο κράτος

Διαδικτυακές αναρτήσεις διοικητικών αποφάσεων για το HIV/AIDS

Έρευνα

Σας έχει σπάσει ποτέ το προφυλακτικό κατά τη διάρκεια μιας ερωτικής επαφής;
Ναι
Όχι
Δεν χρησιμοποιώ

Επικοινωνία

Newsletter

Ανακοινώσεις

Χρήσιμες πληροφορίες

Τηλεφωνική γραμμή για το HIV/AIDS

210-7222222

Δευτέρα - Παρασκευή
09:00 - 21:00